Rusen Zhao

Efficacy and safety of tecotabart vedotin plus toripalimab with or without chemotherapy as first-line treatment for CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma: Phase II study results.

Jin Li, Haiping Jiang, Mingzhu Huang, Lixin Wan et autres

4045 Background: Tecotabart vedotin (TV; LM-302) is a novel and potent MMAE-based ADC targeting CLDN18.2. Previous data (ASCO 2025, abstract#4039) demonstrated promising efficacy and manageable safety profile of TV plus PD-1 inhibitor in patients (pts) with systemic therapy-naive advanced gastric or gastroesophageal …

cn (code pays fourni par la source)

Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody

Jin Li, 寇卫政, L G Sun, Y W Zhao et autres

Abstract Background: MK-2010 (LM-299) is a novel PD-1×VEGF bispecific antibody. We report initial safety and efficacy from the phase 1/2 MK-2010-001/LM299-01-102 study (NCT06650566). Methods: In the dose escalation cohort, participants (pts) with advanced solid tumors received MK-2010 Q2W (0.3-30 mg/kg) or Q3W …

cn, Éthiopie, us (code pays fourni par la source)

Tecotabart vedotin in Claudin 18.2-positive advanced gastric/gastroesophageal junction cancer: A Bayesian phase 1/2 clinical trial

Chunmei Bai, Yi Zheng, Meili Sun, Jieer Ying et autres

cn, us (code pays fourni par la source)

Supplementary Table S5 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 5 Anti-HER2 treatment-related adverse events in patients

Supplementary Table S4 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 4 Immune-related adverse events (irAEs) in patients

Supplementary Table S3 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 3 Summary of the numbers of treatment discontinuations.

Data from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

AbstractPurpose: In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 combination therapies. Patients and Methods: …

Supplementary Table S2 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 2 Sample size calculation.

Supplementary Data S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Trial protocol

Supplementary Table S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

Supplemental table 1 Representativeness of study participants

Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.

Jifang Gong, Chang Liu, Liang Liu, Jun Hu Yao et autres

4010 Background: Targeting tumor-infiltrating Tregs presents a promising strategy to overcome resistance to immunotherapy in cancer treatment. LM-108 is a novel Fc-optimized anti-CCR8 monoclonal antibody designed to selectively deplete tumor-infiltrating Tregs while sparing peripheral Tregs. This pooled analysis of two phase 1/2 …

cn, au (code pays fourni par la source)

Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial

Jieqiong Liu, Chengyang Song, Yaping Yang, Xiangcai Wang et autres

PURPOSE: In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 combination therapies. PATIENTS AND METHODS: …

cn, us, jp, Éthiopie (code pays fourni par la source)